205 related articles for article (PubMed ID: 1284587)
21. The current role of prostatic acid phosphatase and prostate-specific antigen in the management of prostate cancer.
Shetty SD; Cerny JC
Henry Ford Hosp Med J; 1992; 40(1-2):93-8. PubMed ID: 1385363
[TBL] [Abstract][Full Text] [Related]
22. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
Ramos CG; Carvahal GF; Mager DE; Haberer B; Catalona WJ
J Urol; 1999 Nov; 162(5):1587-90. PubMed ID: 10524873
[TBL] [Abstract][Full Text] [Related]
23. Correlation between immunohistochemical patterns and serum levels of PSA and PSAP in prostatic pathology: evaluation of 198 prostatic fine needle biopsies.
Vitali A; Ardoino S; Durante P; Ferro MA; Li Causi F; Parodi C; Sanguineti G; Gaffuri M; Paerachino M; Salvadori RP
Anticancer Res; 1994; 14(4A):1503-7. PubMed ID: 7526771
[TBL] [Abstract][Full Text] [Related]
24. [Prostatic diseases: tumor markers (PAP and PSA) and age at risk].
Manna A; Trasatti L; Cifaldi L; Marchei GG; Reale MG; Marchei P
J Nucl Med Allied Sci; 1990; 34(4 Suppl):91. PubMed ID: 1709213
[No Abstract] [Full Text] [Related]
25. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
[TBL] [Abstract][Full Text] [Related]
26. [Clinical and pathological study of tumor marker in benign prostatic hypertrophy and incidental prostatic cancer].
Sakai N; Ogawa T; Ishibashi Y; Fukuoka H; Sakanishi S
Hinyokika Kiyo; 1991 Jun; 37(6):589-94. PubMed ID: 1716409
[TBL] [Abstract][Full Text] [Related]
27. [Clinical study of tumor markers in prostatic cancer].
Ishihara Y; Fukagai T; Ohta K; Hiromoto Y; Hiramori M; Torii T; Higaki Y; Imamura K
Hinyokika Kiyo; 1990 Apr; 36(4):425-31. PubMed ID: 1696063
[TBL] [Abstract][Full Text] [Related]
28. [Clinical assessment of free serum prostate specific antigen (PSA)].
Chautard D; Daver A; Bali B; Dardari J; Debras B; Colls P; Soret JY
Prog Urol; 1996 Jun; 6(3):368-74. PubMed ID: 8763691
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic value of prostatic acid phosphatase and prostate-specific antigen in patients with prostatic cancer.
Pagani F; Zambolin T; Bonora R; Panteghini M
J Nucl Med Allied Sci; 1990; 34(4 Suppl):85-7. PubMed ID: 1709211
[TBL] [Abstract][Full Text] [Related]
30. Markers of undiagnosed incidental cancer in comparison with clinical prostatic cancer.
Ogawa A; Yoshida A; Kanda T; Sugihara S; Suzuki T; Tamura J; Kobayashi I; Nakazato Y
J Med; 2000; 31(1-2):101-10. PubMed ID: 10998759
[TBL] [Abstract][Full Text] [Related]
31. [Effects of transurethral resection on the serum concentration of prostate specific antigen and prostatic acid phosphatase].
Morote J; de Torres JA
Actas Urol Esp; 1990; 14(5):356-7. PubMed ID: 1705076
[TBL] [Abstract][Full Text] [Related]
32. Role of free to total prostate specific antigen ratio in serum in the diagnosis of prostatic enlargement.
Bhuiyan AK; Kibria SA; Subhan SS
Bangladesh Med Res Counc Bull; 2004 Aug; 30(2):51-9. PubMed ID: 15813483
[TBL] [Abstract][Full Text] [Related]
33. The effect of manipulation of the prostate gland on serum prostate-specific acid phosphatase measured by radioimmunoassay.
Vihko P; Lukkarinen O; Kontturi M; Vihko R
Invest Urol; 1981 Mar; 18(5):334-6. PubMed ID: 6162819
[TBL] [Abstract][Full Text] [Related]
34. Relationship between prostatic acid phosphatase and prostate-specific antigen serum levels and prostatic volume in benign prostate hyperplasia. Pitfall on tumor markers assessment in primary prostatic cancer?
Omacini S; Mione R; Barichello M; Santucci Delli Ponti U; Bolgan A; Contemori GP; Petracco S; Capitanio G; Donisi PM; Gion M
Eur Urol; 1992; 21 Suppl 1():108-10. PubMed ID: 1385128
[TBL] [Abstract][Full Text] [Related]
35. Changes in prostate-specific antigen and prostatic acid phosphatase concentration following prostatic examination in benign prostatic hypertrophy and prostate cancer patients.
Romics I; Galamb L
Eur Urol; 1992; 21 Suppl 1():83-6. PubMed ID: 1385137
[TBL] [Abstract][Full Text] [Related]
36. Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinoma.
Huang CL; Brassil D; Rozzell M; Schellhammer PF; Wright GL
Prostate; 1993; 23(3):201-12. PubMed ID: 7694265
[TBL] [Abstract][Full Text] [Related]
37. [Prostate specific antigen and NF-kB in prostatic disease: relation with malignancy].
Cansino JR; Vera R; Rodríguez de Bethencourt F; Bouraoui Y; Rodríguez G; Prieto A; de la Peña J; Paniagua R; Royuela M
Actas Urol Esp; 2011 Jan; 35(1):16-21. PubMed ID: 21256390
[TBL] [Abstract][Full Text] [Related]
38. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM
Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860
[TBL] [Abstract][Full Text] [Related]
39. Daily variability in human serum prostate-specific antigen and prostatic acid phosphatase: a comparative evaluation.
Dejter SW; Martin JS; McPherson RA; Lynch JH
Urology; 1988 Oct; 32(4):288-92. PubMed ID: 2459831
[TBL] [Abstract][Full Text] [Related]
40. Prostate adenocarcinoma using Gleason scores correlates with prostate-specific antigen and prostate acid phosphatase measurements.
Shih WJ; Gross K; Mitchell B; Collins J; Wierzbinski B; Magoun S; Ryo UY
J Natl Med Assoc; 1992 Dec; 84(12):1049-50. PubMed ID: 1284282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
